Catalog No.: PC-27935Not For Human Use, Lab Use Only.
Atractylenolide I (ATT-I, AT-I) is a sesquiterpene derived from the rhizome of Atractylodes macrocephala within neuroprotective, anti-allergic, anti-inflammatory and anticancer properties, targets and binds proteasome 26S subunit non-ATPase 4 (PSMD4) with MST KD of 0.4 uM, enhances antigen presentation on tumor cells.
Atractylenolide I (ATT-I, AT-I) is a sesquiterpene derived from the rhizome of Atractylodes macrocephala within neuroprotective, anti-allergic, anti-inflammatory and anticancer properties, targets and binds proteasome 26S subunit non-ATPase 4 (PSMD4) with MST KD of 0.4 uM, enhances antigen presentation on tumor cells. Atractylenolide I (ATT-I) promotes CD8+ T cell–mediated tumor cell killing. Atractylenolide I (ATT-I) enhances the antigen-specific T cell responses in MC38 tumor–derived organoids. Atractylenolide I (ATT-I) promotes the activity of immunoproteasome in a PSMD4-dependent manner, binds to PSMD4 and stabilizes the PSMD4 and PSMD7 interaction, leading to enhanced proteasomal activities. Atractylenolide I (ATT-I) promotes antigen presentation and enhances the efficacy of CRC immunotherapy. Atractylenolide I (ATT-I) enhances tumor-infiltrating lymphocytes and antitumor activity of cytotoxic T lymphocytes.
